Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-OSA-2
jRCT2031250677Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Nov 2025
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS), obesity and Overweight comparing Maridebart Cafraglutide with Placebo (2 arms). Primary endpoint: Change in Apnea-hypopnea Index from baseline at Week 52. Started Nov 2025; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesityOverweight
Beyond the preview
Go deeper on jRCT2031250677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250677.